Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer
Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Serum levels of the extracellular domain of HER2/neu (HER2 ECD) have been demonstrated to be associated with clinical outcomes. A disintegrin and metalloproteinase-10, a sheddase of HER2/neu, can drive cancer progression and its activity is inhibited by tissue inhibitor of metalloproteinase-1 (TIMP-1). However, elevated TIMP-1 expression has been a...
Alternative Titles
Full title
Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9af8051c60dd4c4fa6f92df5771b3b5e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9af8051c60dd4c4fa6f92df5771b3b5e
Other Identifiers
ISSN
1477-7819
E-ISSN
1477-7819
DOI
10.1186/1477-7819-10-42
